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A poised fragment library enables rapid synthetic
expansion yielding the ﬁrst reported inhibitors of
PHIP(2), an atypical bromodomain†
Oakley B. Cox,abc Tobias Krojer,a Patrick Collins,c Octovia Monteiro,ab Romain Talon,a
Anthony Bradley,a Oleg Fedorov,ab Jahangir Amin,d Brian D. Marsden,ae
John Spencer,d Frank von Delft*acf and Paul E. Brennan*ab
Research into the chemical biology of bromodomains has been driven by the development of acetyl-lysine
mimetics. The ligands are typically anchored by binding to a highly conserved asparagine residue. Atypical
bromodomains, for which the asparagine is mutated, have thus far proven elusive targets, including
PHIP(2) whose parent protein, PHIP, has been linked to disease progression in diabetes and cancers. The
PHIP(2) binding site contains a threonine in place of asparagine, and solution screening have yielded no
convincing hits. We have overcome this hurdle by combining the sensitivity of X-ray crystallography, used
as the primary fragment screen, with a strategy for rapid follow-up synthesis using a chemically-poised
fragment library, which allows hits to be readily modiﬁed by parallel chemistry both peripherally and in the
core. Our approach yielded the ﬁrst reported hit compounds of PHIP(2) with measurable IC50 values by an
AlphaScreen competition assay. The follow-up libraries of four poised fragment hits improved potency
into the sub-mM range while showing good ligand eﬃciency and detailed structural data.
Introduction
Bromodomains are acetyl-lysine (KAc) reader domains involved
in the modulation of gene expression.1 The druggability of
bromodomains have made them attractive targets for the
treatment of diseases such as cancer and inammation, leading
to the development of a range of chemical probes for the
investigation of bromodomain (Brd) biology (Fig. 1).2 In 2010,
JQ-1 and I-BET were reported as potent inhibitors of the BET
bromodomains (subfamily II)3,4 and subsequent academic and
industrial research has focused on targeting the BET bromo-
domains.5–8 However, recent publications indicated other
subfamilies of the Brd family tree could be targeted by small
molecule inhibitors,9,10 including CBP/p300 (subfamily III),11
BRD7/9 (IV),12,13 BAZ2A/B (V),14,15 CECR2 (I), BRPF1/2/3 (IV) and
SMARCA2/4/PB1 (VIII), as well as the pan-Brd inhibitor, bro-
mosporine (Fig. 1).16
Most Brd inhibitors are anchored by a highly conserved
asparagine (Asn) residue and a network of four water molecules
in the KAc binding pocket. Together the Asn and rst water in
the chain of four donate two H-bonds to a pair of H-bond
acceptors on the inhibitor. The importance of the conserved
Asn residue in inhibitor binding reects its critical role in KAc
recognition of the natural ligand (ESI Fig. S1A†).1 However, only
forty-eight of the sixty-one known human Brds (79%) Brds have
an Asn residue in the KAc binding pocket. The remaining
thirteen Brds (21%) have a tyrosine, threonine or aspartic acid
in place of the asparagine (Fig. 1 and ESI Fig. S1B†). To date, no
inhibitors of these atypical, non-asparagine bromodomains
have been reported.
PHIP(2), an atypical bromodomain
The second bromodomain of the pleckstrin homology domain-
interacting protein (PHIP(2)) is one of the atypical bromodo-
mains. PHIP is believed to mediate the activity of insulin-
receptor (IRS) proteins,17 and has been identied as a possible
marker in melanoma prognosis.18 More recently, PHIP has been
observed to be overexpressed in metastatic melanomas.17 The
PHIP protein contains two bromodomains, PHIP(1) and
PHIP(2). The rst bromodomain, from family VII of the bro-
modomain phylogenetic tree, has no reported crystal or NMR
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structures. However, in 2010 the crystal structure of the second
PHIP bromodomain was deposited in the Protein Data Bank
(PDB) (NMP, PDB ID 3MB3) (Fig. 2), bound to N-methyl pyrro-
lidone but in a ipped conformation compared to typical Brds,
such as CREBBP (PDB ID 3P1D).1
PHIP(2) belongs to the bromodomain subfamily III along-
side CREBBP (Fig. 1).1 The atypical binding site of PHIP(2) is
characterised by a threonine (Thr) residue (T1396) in place of
the conserved asparagine (Fig. 2). Because the Thr side chain is
one atom shorter than Asn, there is space for an additional
water molecule, dubbed the ‘PHIP water’, to mediate an inter-
action between T1396 and the typical water network at the back
of the binding pocket. The water-network is otherwise compa-
rable to the network observed in most Brd binding sites, con-
sisting of four water molecules and anchored by a tyrosine
residue (Y1353). Despite being identied as a druggable Brd,19
to date no small molecule inhibitors of PHIP(2) have been re-
ported. An unpublished screening campaign by the Structural
Genomics Consortium (SGC) did not yield any hits from
a library of approximately seven thousand Brd-focused
compounds.
Fragment based drug discovery by X-
ray crystallography
Fragment based drug discovery (FBDD) has become an
increasingly important tool for nding hit compounds for
diﬃcult targets.20 The technique utilises smaller than drug-like
compounds to identify low potency, high quality leads.
Libraries containing hundreds to thousands of compounds
achieve similar coverage of chemical space as the millions
required for traditional high throughput screening (HTS)
campaigns.21 As a result, FBDD is considerably more aﬀordable
as a hit-nding method and has enjoyed widespread success in
both academia and industry.22
Fig. 1 Bromodomain family tree with sub-families (I–VIII) as deﬁned by Filippakopoulos et al.1 Brds for which SGC Chemical Probes have been
released are highlighted and the structures depicted: SGC-CBP30,11 I-CBP112, (+)-JQ1,3 PFI-1,7 PFI-3, BAZ2-ICR,15 GSK cmpd 3, OF-1, LP99,12 I-
BRD9 and the pan-Brd inhibitor bromosporine.16 Atypical bromodomains are highlighted for which the conserved asparagine residue in the KAc
binding site is replaced by tyrosine (blue), threonine (green) or aspartic acid (purple).
Fig. 2 PHIP(2) (green sticks and ribbons) in complex with NMP (cyan
sticks). The substitution of an Asn for the smaller Thr allows an extra
watermolecule, the PHIP water (red CPK, PW) to ﬁll the space between
T1396 and the usual four Brd waters (red CPK I–IV) (PDB ID: 3MB3).1
This journal is © The Royal Society of Chemistry 2016 Chem. Sci., 2016, 7, 2322–2330 | 2323
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Fragment screening has been especially eﬀective in discov-
ering Brd inhibitors using both focused and diverse
libraries.23,24 Fragments have been optimized into more potent
chemical probes but in all cases the Brds targeted contained the
key Asn residue to anchor an acetyl lysine mimetic fragment.11,25
A major challenge of fragment screening is that, although
fragment sized compounds make high quality interactions with
their targets and bind with high ligand eﬃciency, overall
binding aﬃnity is typically weak due to their small size.26
Therefore the techniques used to detect fragment binding must
be sensitive on the mM to mM scale. Biophysical and
biochemical solution-based techniques are convenient and
widely used but drawbacks include insuﬃcient sensitivity, high
rates of false positives and screening concentrations limited to
low mM.27 In contrast, NMR and X-ray crystallography are ideal
for detecting weak binding by yielding direct structural infor-
mation, although historically both techniques have been labour
intensive and low-throughput. However, in recent years X-ray
crystallography has seen an order-of-magnitude speed-up
thanks to robotics, improved algorithms and detectors and
technical advances at synchrotron facilities.28,29 Moreover, at
beamline I04-1 at Diamond Light Source (DLS),30 other recent
developments around soaking, harvesting and data analysis
have further reduced the eﬀort to such an extent that a 1000-
compound fragment screen by crystallography can be
completed within a week. As a consequence, X-ray crystallog-
raphy is now a viable primary screen for academic and indus-
trial researchers.31
In particular, this makes it realistic to screen by soaking
single compounds per crystal, rather than cocktails, so that
concentrations >100 mM can be achieved, one hundred to one
thousand times higher than possible in solution-based tech-
niques, with accordingly increased sensitivity.31
The very weak hits identied by X-ray screening pose
a practical problem, in that they are in general too weak to be
veried by orthogonal solution assays; yet such information is
a common requirement in medicinal chemistry operations,
especially if the crystallographic evidence is ambiguous. Opti-
mising weak compounds by traditional SAR is equally under-
mined without reliable assay readout in the range of the
compounds' binding aﬃnity. In any case, progressing weak
compounds to potency in general requires changes not only to
the periphery, where conventional SAR operates, but also to the
core of the compound.
To overcome the problem of optimising weak compounds
discovered by high concentration fragment soaking, we report
the design and use of a poised fragment screening library to
identify hits and the parallel synthesis of analogues to deliver
inhibitors with measurable activity. Furthermore, we demon-
strate how the method is eﬀective on the previously intractable
target, PHIP(2).
Results and discussion
Poised fragments
We dene a poised fragment as a fragment synthesised from
a robust and general synthetic reaction such that rapid
elaboration of the fragment hit into a library of analogues can
be done using parallel chemistry. Identication of a poised
bond (or bonds) in a fragment allows the compound to be
deconstructed into at least two synthons (Fig. 3). As a simple
example, an amide bond can be deconstructed into an acid
chloride and an amine. Upon discovery of a poised amide hit,
purchase of similar synthons to those found in the hit allows
the synthesis of a library of analogous amides, which can be
soaked in crystals just days aer the initial hit has been ob-
tained. The result is detailed structural information of the
ligand binding site and, potentially, an improvement in binding
activity large enough to allow measurement using a biophysical
or biochemical assay. Poised chemistry requires reliable, robust
reactions which tolerate a range of substrates and can be per-
formed using a wide range of commercially available starting
materials. The reaction products should be formed in high yield
and contain drug-like functionalities with no known toxicolog-
ical moieties.
In 2011, Roughley and Jordan published an analysis of the
most commonly used reactions in drug discovery.32 The authors
propose the reactions are regularly used because experienced
medicinal chemists know they provide reliable methods to
synthesise drug-like molecules. The top ten reactions identied
by the analysis, including amide coupling, reductive amination
and Suzuki-type aryl–aryl coupling, can be performed using
standardised procedures for a wide range of substrates. The
starting materials for each reaction contain common func-
tionalities which are well represented in commercial supplier
space and are compatible with this diverse range of commercial
compounds. The ten reactions were selected to create poised
scaﬀolds with which to perform substructure searches. The
poised fragment chemical space was further augmented with
twelve heterocycle forming reactions as dened by Hartenfeller
et al.33 and an oxazole formation developed in our own lab.34,35
The complete list of poised scaﬀolds is depicted in Fig. 4A.
Design of poised fragment libraries
To construct an initial poised fragment library, the Diamond
and SGC Poised Fragment Library 1.0 (DSPL1), the large
Fig. 3 Schematic depicting how a poised fragment library can be used
to rapidly synthesise a follow-up library of analogues. If the orange
fragment is identiﬁed as a hit, a library of similar compounds can be
rapidly constructed using parallel synthesis with commercial
analogues of synthons 1 and 2.
2324 | Chem. Sci., 2016, 7, 2322–2330 This journal is © The Royal Society of Chemistry 2016
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collection of SGC fragments assembled in-house and from
collaborator collections (11 677 in total), was analysed for the
presence of poised substructures and prevalent synthons. Of the
eleven thousand SGC fragments, 2347 could be considered
poised by our denition. As screening the entire set of >2000
poised SGC fragments would not have been possible and as
some of the compounds were very similar to each other,
a subset of 406 compounds was selected for DSPL1 ensuring
diversity of chemotype and poised classication. All
compounds were clustered by ngerprints using the default
method in MolSo's ICM to give 233 clusters. The compounds
in DPSL1 were selected based on diversity of structure and
diversity of poised motif (Fig. 4).
Encouraged by the success of soaking DSPL1 in PHIP(2) (see
below), a second generation poised library was designed
(DSPL2). DSPL2 was designed using similar methodology as
DSPL1 but was assembled entirely from commercial fragments
to ensure that anyone could purchase and use the library. The
ZINC fragment-like library was downloaded36 and ltered based
on vendor ID for suppliers from which we had routinely sourced
compounds, yielding192k compounds. Filters were applied to
the compound library to ensure drug-like characteristics (ESI
Fig. S2†). From the resulting library of 41 271 compounds,
28 438 (68%) were found to be poised by our denition. While
initially surprising that such a large number of commercial
fragments could be synthesised by only twenty-one diﬀerent
chemical reactions, we believe this reects the very limited
coverage of potential synthetic compounds by commercial
vendors. Further lters were applied to ensure each compound
is compatible with the reaction by which it was found to be
poised. For example an amine substituted amide would be
removed from the library as an asymmetric diamine synthons
could give a mixture of amides if used to synthesise a poised
fragment. Compounds without commercially available starting
materials were also removed.
In theory, the resulting library of 10 448 compounds covers
the whole of commercially accessible poised fragment space
using our chosen reactions. The library is dominated by amides,
with 55.1% of fragments containing a poised amide bond; ether
bonds (18.2%) and reductive amination products (10.2%) were
also heavily represented. The least represented chemistries were
Sonogashira products (0.2%) and sulfonamides (2.0%) (ESI
Fig. S3†). Unfortunately, poised heterocyclic reactions were
observed in just 2.2% of the compounds, despite thirteen reac-
tions (only eight of which were found to be present) being used
to identify such fragments and the importance of such scaﬀolds
in drugs and chemical tools.38 The nding demonstrates the
bias of commercially available compounds towards the most
commonly used reactions identied by Roughley and Jordan.32
Finally, the USRCAT algorithm was used to ensure chemical
diversity was maintained upon selecting 1000 compounds for
DSPL2 from the total of >10 000.39 USRCAT was selected
because it was believed the additional conformation informa-
tion makes it a superior measure of diversity for library design
in comparison to traditional chemical diversity measures
(MACCS, Morgan ngerprints, etc.). Although DSPL1 and 2 do
not contain the exact same compounds, they were constructed
using similar principles and occupy similar chemical space (ESI
Fig. S4†). The full identities of DSPL1 and DSPL2 can be
downloaded as sdf les from the ESI.†
Soaking PHIP(2) with DSPL1
To test the utility of the poised fragment library methodology,
the PHIP(2) Brd was screened using high concentration crystal
soaking. The PHIP(2) Brd was crystallised in its apo-form to
generate enough crystals to screen DSPL1.40
Fig. 4 Design of DSPL1 (A) scaﬀolds used to identify poised fragments. Core scaﬀolds based upon themost commonly usedmedicinal chemistry
reactions as described by Roughley and Jordan.32 Heterocycle scaﬀolds based on reactions described by Hartenfeller et al.37 (B) Poised reaction
motif vs. cluster. Circle size represents the number of compounds in each group. 407 compounds for DSPL1 were selected from all SGC poised
fragments based on diversity and poised reaction motif.
This journal is © The Royal Society of Chemistry 2016 Chem. Sci., 2016, 7, 2322–2330 | 2325
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Due to the relatively potent binding of DMSO to Brds,41
compounds were dissolved in ethylene glycol at a nominal
concentration of 400 mM. The supernatant of compounds
which did not fully dissolve was used with the assumption it was
a saturated solution. The solutions were soaked into protein
crystals in crystal buﬀer in a 1 : 1 volume ratio to give an
approximate nal compound concentration of 200 mM. All 406
poised fragments in DSPL1 were soaked into PHIP(2) Brd crys-
tals and when the structures were solved, compounds 1–4 were
found to have bound to the protein (1.2% hit rate).
All of the poised fragment hits 1–4 bound to PHIP(2) Brd in
the KAc recognition pocket (Fig. 5). The thiourea sulfur of
compound 1 displaces water I at the back of the binding pocket
allowing the formation of hydrogen bonds with Y1353 and
water II. The secondary thiourea nitrogen forms an H-bond to
T1396 via the structural PHIP water (PW). The primary thiourea
nitrogen lies in the hydrophilic pocket made by waters II, III and
IV. The phenyl ring of compound 1 makes an edge–face
aromatic interaction with Y1350, which is shied signicantly
towards the ligand compared to the NMP-bound conformation
(Fig. 2). The ortho-methyl substituent on the phenyl ring makes
additional interactions with the hydrophobic residues I1403
and P1340.
Compound 2 binds like a classical acetyl-lysine mimetic
(Fig. 5B). The acetyl group lies deep in the binding pocket
allowing the methyl group to sit in the hydrophobic pocket
created by the four structural waters in a manner analogous to
inhibitors of typical Brds and acetyl lysine. The carbonyl oxygen
interacts with T1396 through a hydrogen bond mediated by the
PHIP water. Like compound 1, the phenyl ring of compound 2
appears to make an edge–face aromatic interaction with the
shied Y1350 side chain, allowing the 2,6-dichloro substituents
to occupy the hydrophobic pockets formed by V1345 and I1403
above and below the ring.
Oxazoles 3 and 4 share the same binding mode. The primary
amine and oxazole oxygen form a donor and acceptor
interaction with T1396 (Fig. 5C, compound 4 not shown for
clarity). Y1350 forms an H-bond to the oxazole nitrogen. The
orientation of the oxazole rings of compounds 3 and 4 is
striking, and allows for the respective lipophilic benzyl and
isobutyl groups to lie in the methyl-binding pocket created by
the four structural waters. Furthermore, the 4-cyano and 4-
amino groups of compounds 3 and 4 interact with a neigh-
bouring protein in the crystal lattice. The cyano group acts as an
H-bond acceptor with the backbone N–H of D1352, while the
amino group forms a salt bridge with the D1352 carboxylate
group.
Rapid synthesis of follow-up libraries
As each of the hit compounds, 1–4, is a poised fragment, the
three distinct series were rapidly populated with analogues via
parallel, solution-phase synthesis.
(a) Thioureas. The thioureas were synthesised by the
sequential addition of the relevant amines to 1,10-thio-
carbonyldiimidazole (thio-CDI) (Scheme 1). Analysis of the
crystal data obtained for compound 1 indicated a lipophilic
pocket adjacent to the 3-position of the benzene ring so
emphasis was placed on exploring this position. Substitution of
the terminal thiourea nitrogen was also proposed in an attempt
to displace more of the structural waters at the back of the
binding site. In total thirty-ve compounds were proposed for
synthesis and twenty-nine (83%) were synthesised and puried
in moderate to good yield within two weeks (Table 1,
compounds 5–11 and ESI Table S1,† compounds s1–s22).
The thiourea series was tested for inhibition of PHIP(2)
ligand binding using an AlphaScreen assay based upon
a previously reported method.41 Ligand eﬃciencies (LE) were
calculated using the relationship described by Hopkins et al. in
which LE is taken to be proportional to the IC50 contribution per
non-hydrogen atom in the ligand.26
The original fragment hit 1 had pIC50 of 3.11 in the
AlphaScreen assay. Addition of a substituent at the 3-position of
Fig. 5 PHIP(2) (green sticks, ribbons and mesh (2Fo-Fc)) in complex with fragment hits. (A) Thiourea 1 (cyan sticks and mesh (2Fo-Fc)) displaces
waters I. (B) N-Benzylacetamide 2 (purple sticks and mesh (2Fo-Fc)) binds with all water molecules intact and forms an edge–face interaction
with Y1350. (C) Oxazole 3 (cyan sticks and mesh (2Fo-Fc)) forms H-bonds to PW (black dashed line). PHIP(2) orientation has been changed for
clarity. (D) Overlay of compounds 1–3 in PHIP(2). In (C) and (D) water II is hidden behind water I.
2326 | Chem. Sci., 2016, 7, 2322–2330 This journal is © The Royal Society of Chemistry 2016
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the phenyl ring to give compounds 5–8 increased potency. The
methyl derivative 6 and the triuoromethyl derivative 7 had
improved pIC50  3.8. The addition of a methyl group at the 6-
position of the phenyl ring to give compound 9 slightly
increased potency to pIC50 3.32 as did methylation of the
primary thiourea nitrogen to give compound 10 (pIC50 3.38).
The SAR improvements were not cumulative (see ESI,†
compounds s1–s20), but replacement of 2-methylphenyl with 2-
chlorophenyl on the methylated thiourea, giving compound 11,
improved PHIP(2) activity to pIC50 3.89. The LE of fragment hit 1
was calculated to be 0.40. The value was increases to 0.45 for the
most potent thioureas 6 and 11.
When the thiourea compounds 5–11 were subjected to
soaking experiments with PHIP(2) crystals, two of the most
potent compounds, 6 and 8, appeared to bind in the PHIP(2)
KAc recognition site (ESI Fig. S5A and B†). The apparent poses
are similar to compound 1, displacing structural water.
(b) N-Benzyl amides. The N-benzyl amides were synthesised
using amine derivatisation with acyl chlorides (Scheme 1).
Substitution of the benzene ring was proposed as well as
extension of the acetyl group with the aim of displacing struc-
tural waters. In total twelve analogues were proposed for
synthesis and eleven (92%) were synthesised in good to excel-
lent yield within one week (Table 2, compounds 12–17 and ESI
Table S2,† compounds s23–s27).
Compounds 2 and 12–17 were tested for inhibition of
PHIP(2) ligand binding using the AlphaScreen assay. The orig-
inal fragment hit 2 was inactive against PHIP(2) at the highest
possible assay concentration and would not have been detected
as a hit if AlphaScreen had been used as the primary screen.
Attempts to modify the acetyl amide group or the benzene ring
gave no improvements in potency. The exception was the 2,6-
dimethoxy analogue 12 with a pIC50 of 3.72 and LE of 0.35.
The benzyl amide compounds 12–17 were soaked into
PHIP(2) crystals. Surprisingly the inactive compounds 13 and 14
were found to bind in the KAc binding site as well as the active
compound 12. Compound 12 has the same binding mode as
fragment hit 2, with the 2,6-dimethoxy substitution pattern on
the benzene ring occupying the V1345 and I1403 lipophilic
pockets above and below the ring (Fig. 6A).
Alcohol 13 binds in the same position as fragment hit 2, with
the additional hydroxyl group making an H-bond interaction to
the protein backbone at P1340 (Fig. 6B). In contrast, the N-
methyl group of the tertiary amide 14 forms a hydrophobic
interaction with the P1340 sidechain (Fig. 6C).
Despite binding in a similar way to the other amide
compounds, tertiary amide 14 appears to displace structural
water II.
The activity and crystallographic data resulted in three new
compounds being proposed for synthesis. All three were
synthesized in low yield within two weeks (Table 2, compounds
15–17). The 2,6-dimethoxy analogue of alcohol 13 (compound
15) is inactive against PHIP(2) but appears to bind to the protein
when subjected to soaking experiments (ESI Fig. S5C†).
Overlay of fragment hit 2 with the previously reported
NMP-bound structure (Fig. 2) showed good overlap between
the amide binding modes for each compound. A scaﬀold
merging approach was adopted and the lactam containing
compounds 16 and 17 proposed and synthesised. Both lac-
tams were found to inhibit the activity of PHIP(2). pIC50’s of
3.25 and 3.51 for compounds 16 and 17 respectively
demonstrate good activity but LE of only 0.27. The best
compound of the amide series, compound 12, has a calcu-
lated LE of 0.35.
(c) Oxazoles. The aminooxazoles 3–4, 18–22 and s38–s46
were synthesised by addition of aminomalononitrile p-tolue-
nesulfonate to the relevant acyl chloride following a previously
published method (Scheme 1).34 The fragment hits 3 and 4
demonstrated good activity against PHIP(2) with pIC50’s of 3.23
and 3.57 respectively (Table 3). The cyclopropyl analogue 18
showed a pIC50 of 3.48, comparable to the isobutyl hit 4.
Scheme 1 Reagents and conditions: (a) amine 1, thio-CDI, DCM, rt, 30
min, then amine 2, rt, 12 h. (b) Triethylamine, DCM, rt, 3 h. (c) 4-Tol-
uenesulfonic acid, NMP, MW irradiation, 120 C.
Table 1 Synthesis and screening of thioureas 1, 5–11
Cmpd R1 R3 Yield
a X-tal soakb PHIP(2) pIC50
d LE
1 2-Me H 66% Success 3.11  0.06 (2) 0.40
5 2-Me-3-OMe H 71% Error 2.97  0.18 (2) 0.32
6 2,3-Me2 H 12% Success
c 3.78  0.06 (2) 0.45
7 2-Me-3-CF3 H 33% NL 3.85  0.21 (2) 0.36
8 2-Me-3-Cl H 26% Successc 3.59  0.03 (2) 0.42
9 2,6-Me2 H 8% NL 3.32  0.08 (2) 0.39
10 2-Me Me 14% NL 3.38  0.30 (2) 0.39
11 2-Cl Me 19% NL 3.89  0.05 (2) 0.45
a Synthesised using procedure described in Scheme 1. NI: not isolated.
b NL: no ligand found in model. Error: experiment failure during
soaking, at beamline or during data processing or model renement.
c Binding pose uncertain as a result of partial occupancy. d By
AlphaScreen peptide displacement assay.
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However the isopropyl analogue 19 showed complete loss of
activity in the AlphaScreen. The 4-chlorobenzyl derivative 20
showed the best activity with a pIC50 of 3.95, although the bulky
phenyl ring ensured LE was kept to just 0.35. In comparison, the
lighter compounds 4 and 18 have LEs of 0.42 and 0.44 respec-
tively. The cyclohexyl analogue 21 showed good activity (pIC50 ¼
3.31) but substitution of the 5-amino group withN-pyrrolidine to
give compound 22 increased the pIC50 by 0.4. The observation
indicates the amine group interacts with T1396 as an H-bond
acceptor and a tertiary amine can be tolerated at the 5-position
of the oxazole ring. Despite the good activity of the oxazole
series, no further crystal structures of the bound ligand were
observed following soaking experiments.
X-ray structures in screening and follow-up
The need for screening at very high-concentrations has been
borne out by the hits identied for PHIP(2) through the X-ray
approach, where conventional solution screening using far
more compounds had yielded no hits. Moreover, as we have
now shown at DLS beamline I04-1 that crystal-based
screening is achievable with throughput comparable to NMR,
we foresee a re-emergence of its popularity over the histori-
cally more practical but less sensitive solution-based
techniques.
In contrast, the assessment of the follow-up compounds
requires diﬀerent criteria. Our observation that some of the
more potent compounds such as 11 are not visible in the crystal
structure upon soaking is line with common anecdotal experi-
ence, that crystallographic clarity is not a useful ranking crite-
rion for micromolar compounds. In the fragment eld, this
manifests as the widely-reported lack of hit overlap between
techniques.42 A variety of factors inuence whether soaking is
successful, including compound solubility in the crystallization
buﬀer.
Fig. 6 PHIP(2) (green sticks and ribbons) in complex with N-benzy-
lacetamides 12–14 (cyan sticks). Electron density shown as green and
blue mesh (2Fo-Fc). (A) The amide 12 binds in the same pose as
fragment hit 2. (B) The hydroxyacetamide 13 forms an H-bond to
P1340. (C) Tertiary amide 14 appears to displace structural water II.
Table 3 Synthesis and screening of oxazoles 3–4, 18–22
Cmpd R1 Yield
a X-tal soakc PHIP(2) pIC50
d LE
3 Bn 62% Success 3.23  0.10 (2) 0.30
4 iBu 42% Success 3.57  0.10 (2) 0.42
18 Prc 93% NL 3.48  0.03 (2) 0.44
19 iPr 54% NL <2.30 (2) <0.29
20 4-Cl-Bn 46% Error 3.95  0.03 (2) 0.35
21 Hexc 71% NL 3.31  0.06 (2) 0.33
22 Hexc 30%b NL 3.71  0.16 (2) 0.29
a Synthesised using procedure described in Scheme 1 unless stated.
b Over three steps. See Spencer et al. for details.34 c NL: no ligand
found in model. Error: experiment failure during soaking, at beamline
or during data processing or model renement. d By AlphaScreen
peptide displacement assay.
Table 2 Synthesis and screening of N-benzylamides 2, 12–17
Cmpd R1 R3
a Yieldb X-tal soakf PHIP(2) pIC50
h LE
2 2,6-Cl2 C–Me 44% Success <2.30 (2) <0.25
12 2,6-(OMe)2 C–Me 79% Success 3.72  0.04 (2) 0.35
13 2,6-Cl2 C–CH2OH 15%
c Success <2.30 (2) <0.23
14 2,6-Cl2 N–Me, C–Me 83% Success <2.30 (2) <0.23
15 2,6-(OMe)2 C–CH2OH 23%
d Successg <2.30 (2) <0.20
16 2,6-(OMe)2 5-Lactam 6%
e NL 3.25  0.04 (2) 0.27
17 2,6-(OMe)2 6-Lactam 18%
e NL 3.51  0.04 (2) 0.27
a R3 ¼ N–H unless stated.
b Synthesised using procedure described in Scheme 1 unless stated. c Reagents and conditions: EDC, DMAP,
triethylamine, DMF, rt. d Over three steps. See ESI for details. e Triethylamine, AcN, rt. f NL: no ligand found in model. g Binding pose
uncertain as a result of partial occupancy. h By AlphaScreen peptide displacement assay.
2328 | Chem. Sci., 2016, 7, 2322–2330 This journal is © The Royal Society of Chemistry 2016
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Conclusions
We have designed and assembled a library of poised fragments
to enable rapid elaboration of fragment hits weak enough to be
identied only by X-ray crystallography. The identity of the
library, called the Diamond SGC Poised Library 2.0 (DSPL2), is
freely available (ESI†). The library will be regularly updated to
reect ndings regarding compound suitability for soaking,
storage and chemical elaboration.
Our in-house poised fragments were used in combination
with a novel medium-throughput crystallographic screen to
identify the rst reported inhibitors of PHIP(2), an atypical
bromodomain. By exclusively utilising poised fragments in our
screen, we have rapidly generated follow-up leads and shown
increases in compound activity alongside highly detailed
structural data.
The thiourea 1 displaces one of the structural waters at the
back of the PHIP(2) binding site, something rarely seen in other
bromodomain ligand–protein complexes. The series was
expanded to give highly ligand eﬃcient inhibitors with IC50's of
100–200 mM and calculated LE values greater than 0.40
(compounds 6, 7, and 11).
Amide 2 was found to be inactive in an AlphaScreen assay
against PHIP(2), yet one round of poised synthesis yielded
compound 12with an IC50 of 190 mMand LE 0.35. Structural data
from AlphaScreen-inactive compounds show displacement of
structural waters and allowed further development of the series.
The 5- and 6-member lactams, 16 and 17, showed sub-millimolar
activity and provide a number of additional vectors for elabora-
tion into unexploited regions of the PHIP(2) binding pocket.
The binding mode of the aminooxazoles 3 and 4 appears to
be driven by interactions with T1396, with no displacement of
the structural waters or the PHIP water deeper in the binding
pocket. The 2-isobutyl and 2-cyclopropyl oxazoles, 4 and 18,
show excellent ligand eﬃciency, with IC50's 226 mM and 329 mM
respectively and LE > 0.40.
Ongoing studies are focusing on improving the aﬃnities of
the PHIP(2) hit series reported here with the aim of developing
a viable PHIP(2) chemical probe to help further explore the role
of this Brd in disease, notably cancer. In parallel, through the
SGC's network of synthetic chemistry collaborators, we are
actively expanding our poised fragment library beyond the
simple chemistry described here with compounds derived from
sp3 rich, stereochemically controlled poised reactions.
We submit that the use of a crystallographic primary screen
followed by rapid poised chemistry to generate a follow-up
library oﬀers a new, powerful method in hit discovery and lead
series selection which can be utilised by both academic and
industrial researchers. The success in nding eﬃcient hits for
the low druggability PHIP(2) bromodomain indicates the power
of this method in addressing diﬃcult protein–protein interac-
tion targets.
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